These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23312439)

  • 1. How should we release vitreomacular traction: surgically, pharmacologically, or pneumatically?
    Johnson MW
    Am J Ophthalmol; 2013 Feb; 155(2):203-205.e1. PubMed ID: 23312439
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravitreal injection of expansile perfluoropropane (c(3)f(8)) for the treatment of vitreomacular traction.
    Rodrigues IA; Stangos AN; McHugh DA; Jackson TL
    Am J Ophthalmol; 2013 Feb; 155(2):270-276.e2. PubMed ID: 23164159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel possibility of vitreomacular traction treatment.
    Michalska-Małecka K; Witek K; Sierocka-Stępień J; Wyględowska-Promieńska D; Nowak M
    Acta Ophthalmol; 2016 Dec; 94(8):e818-e819. PubMed ID: 27167161
    [No Abstract]   [Full Text] [Related]  

  • 4. Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when?
    Ziemssen F; Bartz-Schmidt KU; Dimopoulos S
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):615-6. PubMed ID: 26887826
    [No Abstract]   [Full Text] [Related]  

  • 5. Microplasmin for vitreomacular traction.
    Udaondo P; Diaz-Llopis M; Garcia-Delpech S; Salom D; Arevalo JF
    Ophthalmology; 2010 Sep; 117(9):1859, 1859.e1; author reply 1859-60. PubMed ID: 20816250
    [No Abstract]   [Full Text] [Related]  

  • 6. Incomplete release of vitreomacular attachments after intravitreal ocriplasmin.
    Jeng KW; Baumal CR; Witkin AJ; Witkin SR; Wiegand TW; Waheed NK
    Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):271-4. PubMed ID: 25707057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.
    Stalmans P; Duker JS; Kaiser PK; Heier JS; Dugel PU; Gandorfer A; Sebag J; Haller JA
    Retina; 2013; 33(10):2003-11. PubMed ID: 23881226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitreomacular traction syndrome.
    Martins TG; Martins TG; Rodriguez EE; Costa AL
    Einstein (Sao Paulo); 2015; 13(2):334-5. PubMed ID: 25946051
    [No Abstract]   [Full Text] [Related]  

  • 9. Anatomic and visual outcomes of vitrectomy for vitreomacular traction syndrome.
    Witkin AJ; Patron ME; Castro LC; Reichel E; Rogers AH; Baumal CR; Duker JS
    Ophthalmic Surg Lasers Imaging; 2010; 41(4):425-31. PubMed ID: 20608611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathology of Internal Limiting Membrane Specimens Following Intravitreal Injection of Ocriplasmin.
    Schumann RG; Wolf A; Mayer WJ; Compera D; Hagenau F; Ziada J; Kampik A; Haritoglou C
    Am J Ophthalmol; 2015 Oct; 160(4):767-78. PubMed ID: 26133247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correspondence.
    Primavera V; Querques G
    Retina; 2014 Dec; 34(12):e39-40. PubMed ID: 25407235
    [No Abstract]   [Full Text] [Related]  

  • 12. Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology.
    Willekens K; Abegão Pinto L; Vandewalle E; Stalmans I; Stalmans P
    Retina; 2015 Jun; 35(6):1135-43. PubMed ID: 25719990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reply: To PMID 23881226.
    Stalmans P; Duker JS
    Retina; 2015 Apr; 35(4):e28-9. PubMed ID: 25807179
    [No Abstract]   [Full Text] [Related]  

  • 14. EFFICACY AND SAFETY OF TREATMENT OPTIONS FOR VITREOMACULAR TRACTION: A Case Series and Meta-Analysis.
    Yu G; Duguay J; Marra KV; Gautam S; Le Guern G; Begum S; Sharifzadeh A; Arroyo JG
    Retina; 2016 Jul; 36(7):1260-70. PubMed ID: 26783988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern®.
    Flaxel CJ; Adelman RA; Bailey ST; Fawzi A; Lim JI; Vemulakonda GA; Ying GS
    Ophthalmology; 2020 Feb; 127(2):P145-P183. PubMed ID: 31757497
    [No Abstract]   [Full Text] [Related]  

  • 16. Early evolution of the vitreomacular interface and clinical efficacy after ocriplasmin injection for symptomatic vitreomacular adhesion.
    Meyer JC; Shah GK; Blinder KJ; Waheed NK; Reichel E; Stalmans P; Singer M; Tewari A
    Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):209-16. PubMed ID: 25707046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumatic vitreolysis for symptomatic vitreomacular traction: case report.
    Hernandez Bel L; Cervera Taulet E; Castro Navarro V; Montero Hernández J; Navarro Palop C; Chiarri Toumet C
    Arch Soc Esp Oftalmol (Engl Ed); 2018 Jan; 93(1):e1-e2. PubMed ID: 28728952
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: subgroup analyses from two randomized trials.
    Haller JA; Stalmans P; Benz MS; Gandorfer A; Pakola SJ; Girach A; Kampik A; Jaffe GJ; Toth CA;
    Ophthalmology; 2015 Jan; 122(1):117-22. PubMed ID: 25240630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
    Hong J; Deng SX; Xu J
    N Engl J Med; 2012 Nov; 367(21):2053; author reply 2054. PubMed ID: 23171110
    [No Abstract]   [Full Text] [Related]  

  • 20. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
    Rao RC; Dlouhy BJ
    N Engl J Med; 2012 Nov; 367(21):2053; author reply 2054. PubMed ID: 23171109
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.